Examinando por Autor "Rojas-Gómez, Diana Marcela"
Mostrando 1 - 2 de 2
Resultados por página
Opciones de ordenación
Ítem New insights on the role of connexins and Gap Junctions Channels in adipose tissue and Obesity(MDPI, 2021) González-Casanova, Jorge Enrique; Durán-Agüero, Samuel; Caro-Fuentes, Nelson Javier; Gamboa-Arancibia, Maria Elena; Tamara, Bruna; Bermúdez, Valmore; Rojas-Gómez, Diana MarcelaDue to the inability to curb the excessive increase in the prevalence of obesity and overweight, it is necessary to comprehend in more detail the factors involved in the pathophysiology and to appreciate more clearly the biochemical and molecular mechanisms of obesity. Thus, understanding the biological regulation of adipose tissue is of fundamental relevance. Connexin, a protein that forms intercellular membrane channels of gap junctions and unopposed hemichannels, plays a key role in adipogenesis and in the maintenance of adipose tissue homeostasis. The expression and function of Connexin 43 (Cx43) during the different stages of the adipogenesis are differentially regulated. Moreover, it has been shown that cell–cell communication decreases dramatically upon differentiation into adipocytes. Furthermore, inhibition of Cx43 degradation or constitutive overexpression of Cx43 blocks adipocyte differentiation. In the first events of adipogenesis, the connexin is highly phosphorylated, which is likely associated with enhanced Gap Junction (GJ) communication. In an intermediate state of adipocyte differentiation, Cx43 phosphorylation decreases, as it is displaced from the membrane and degraded through the proteasome; thus, Cx43 total protein is reduced. Cx is involved in cardiac disease as well as in obesity-related cardiovascular diseases. Different studies suggest that obesity together with a high-fat diet are related to the production of remodeling factors associated with expression and distribution of Cx43 in the atrium.Ítem Specialized Proresolving Lipid Mediators: A Potential Therapeutic Target for Atherosclerosis(MDPI, 2022) Salazar, Juan; Pirela, Daniela; Nava, Manuel; Castro, Ana; Angarita, Lissé; Parra, Heliana; Durán-Agüero, Samuel; Rojas-Gómez, Diana Marcela; Galbán, Néstor; Añez, Roberto; Chacín, Maricarmen; Diaz, Andrea; Villasmil, Nelson; Bautista De Sanctis, Juan; Bermúdez, ValmoreCardiovascular disease (CVD) is a global public health issue due to its high morbidity, mortality, and economic impact. The implementation of innovative therapeutic alternatives for CVD is urgently required. Specialized proresolving lipid mediators (SPMs) are bioactive compounds derived from ω-3 and ω-6 fatty acids, integrated into four families: Lipoxins, Resolvins, Protectins, and Maresins. SPMs have generated interest in recent years due to their ability to promote the resolution of inflammation associated with the pathogeneses of numerous illnesses, particularly CVD. Several preclinical studies in animal models have evidenced their ability to decrease the progression of atherosclerosis, intimal hyperplasia, and reperfusion injury via diverse mechanisms. Large-scale clinical trials are required to determine the effects of SPMs in humans. This review integrates the currently available knowledge of the therapeutic impact of SPMs in CVD from preclinical and clinical studies, along with the implicated molecular pathways. In vitro results have been promising, and as such, SPMs could soon represent a new therapeutic alternative for CVD.